## Silvia Monticone

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5899709/publications.pdf

Version: 2024-02-01

98 papers 5,590 citations

94433 37 h-index 72 g-index

99 all docs 99 docs citations 99 times ranked 3627 citing authors

#	Article	IF	CITATIONS
1	Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes and Endocrinology,the, 2018, 6, 41-50.	11.4	582
2	Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in PrimaryÂCareÂPractice. Journal of the American College of Cardiology, 2017, 69, 1811-1820.	2.8	520
3	Long-Term Cardio- and Cerebrovascular Events in Patients With Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4826-4833.	3.6	348
4	Genetic Spectrum and Clinical Correlates of Somatic Mutations in Aldosterone-Producing Adenoma. Hypertension, 2014, 64, 354-361.	2.7	248
5	Prevalence, Clinical, and Molecular Correlates of <i>KCNJ5</i> Mutations in Primary Aldosteronism. Hypertension, 2012, 59, 592-598.	2.7	246
6	Stem Cell-Derived Extracellular Vesicles and Immune-Modulation. Frontiers in Cell and Developmental Biology, 2016, 4, 83.	3.7	226
7	<i>KCNJ5</i> Mutations in European Families With Nonglucocorticoid Remediable Familial Hyperaldosteronism. Hypertension, 2012, 59, 235-240.	2.7	176
8	Somatic <i>ATP1A1</i> , <i>ATP2B3</i> , and <i>KCNJ5</i> Mutations in Aldosterone-Producing Adenomas. Hypertension, 2014, 63, 188-195.	2.7	151
9	Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension â—. Journal of Hypertension, 2020, 38, 1919-1928.	0.5	151
10	Adrenal vein sampling in primary aldosteronism: towards a standardised protocol. Lancet Diabetes and Endocrinology,the, 2015, 3, 296-303.	11.4	134
11	Guidelines for primary aldosteronism. Journal of Hypertension, 2016, 34, 2253-2257.	0.5	134
12	Effect of <i> KCNJ5 </i> Mutations on Gene Expression in Aldosterone-Producing Adenomas and Adrenocortical Cells. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1567-E1572.	3.6	130
13	Prevalence and Characteristics of Familial Hyperaldosteronism. Hypertension, 2011, 58, 797-803.	2.7	128
14	Immunohistochemical, genetic and clinical characterization of sporadic aldosterone-producing adenomas. Molecular and Cellular Endocrinology, 2015, 411, 146-154.	3.2	115
15	18-Hydroxycorticosterone, 18-Hydroxycortisol, and 18-Oxocortisol in the Diagnosis of Primary Aldosteronism and Its Subtypes. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 881-889.	3.6	105
16	Role of KCNJ5 in familial and sporadic primary aldosteronism. Nature Reviews Endocrinology, 2013, 9, 104-112.	9.6	101
17	Effect of Adrenocorticotropic Hormone Stimulation During Adrenal Vein Sampling in Primary Aldosteronism. Hypertension, 2012, 59, 840-846.	2.7	87
18	A Novel Y152C KCNJ5 Mutation Responsible for Familial Hyperaldosteronism Type III. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1861-E1865.	3.6	86

#	Article	IF	Citations
19	Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma. Hypertension, 2018, 71, 317-325.	2.7	77
20	Liddle Syndrome: Review of the Literature and Description of a New Case. International Journal of Molecular Sciences, 2018, 19, 812.	4.1	69
21	The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism. International Journal of Cardiology: Hypertension, 2020, 5, 100029.	2.2	69
22	Visinin-Like 1 Is Upregulated in Aldosterone-Producing Adenomas With <i>KCNJ5</i> Mutations and Protects From Calcium-Induced Apoptosis. Hypertension, 2012, 59, 833-839.	2.7	64
23	High-salt diet increases glomerular ACE/ACE2 ratio leading to oxidative stress and kidney damage. Nephrology Dialysis Transplantation, 2012, 27, 1793-1800.	0.7	63
24	Clinical Management and Outcomes of Adrenal Hemorrhage Following Adrenal Vein Sampling in Primary Aldosteronism. Hypertension, 2016, 67, 146-152.	2.7	63
25	Renal damage in primary aldosteronism. Journal of Hypertension, 2020, 38, 3-12.	0.5	63
26	Aldosterone Suppression on Contralateral Adrenal During Adrenal Vein Sampling Does Not Predict Blood Pressure Response After Adrenalectomy. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4158-4166.	3.6	62
27	Diagnostic accuracy of aldosterone and renin measurement by chemiluminescent immunoassay and radioimmunoassay in primary aldosteronism. Journal of Hypertension, 2016, 34, 920-927.	0.5	61
28	Prevalence of Hypokalemia and Primary Aldosteronism in 5100 Patients Referred to a Tertiary Hypertension Unit. Hypertension, 2020, 75, 1025-1033.	2.7	60
29	Comparison of Automated Office Blood Pressure With Office and Out-Off-Office Measurement Techniques. Hypertension, 2019, 73, 481-490.	2.7	57
30	A Case of Severe Hyperaldosteronism Caused by a De Novo Mutation Affecting a Critical Salt Bridge Kir3.4 Residue. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E114-E118.	3.6	53
31	Concurrent primary aldosteronism and subclinical cortisol hypersecretion. Journal of Hypertension, 2011, 29, 1773-1777.	0.5	50
32	Is Primary Aldosteronism Still Largely Unrecognized?. Hormone and Metabolic Research, 2017, 49, 908-914.	1.5	50
33	Development and Validation of Prediction Models for Subtype Diagnosis of Patients With Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3706-e3717.	3.6	47
34	GENETICS IN ENDOCRINOLOGY: The expanding genetic horizon of primary aldosteronism. European Journal of Endocrinology, 2018, 178, R101-R111.	3.7	46
35	Understanding primary aldosteronism: impact of next generation sequencing and expression profiling. Molecular and Cellular Endocrinology, 2015, 399, 311-320.	3.2	45
36	Primary Aldosteronism and Obstructive Sleep Apnea. Hypertension, 2019, 74, 1532-1540.	2.7	45

3

#	Article	IF	CITATION
37	Teratocarcinoma-Derived Growth Factor-1 Is Upregulated in Aldosterone-Producing Adenomas and Increases Aldosterone Secretion and Inhibits Apoptosis In Vitro. Hypertension, 2010, 55, 1468-1475.	2.7	43
38	Is There a Role for Genomics in the Management of Hypertension?. International Journal of Molecular Sciences, 2017, 18, 1131.	4.1	40
39	Subtype Diagnosis of Primary Aldosteronism: Is Adrenal Vein Sampling Always Necessary?. International Journal of Molecular Sciences, 2017, 18, 848.	4.1	40
40	Adrenal disorders in pregnancy. Nature Reviews Endocrinology, 2012, 8, 668-678.	9.6	37
41	<i>KCNJ5</i> Mutations Are the Most Frequent Genetic Alteration in Primary Aldosteronism. Hypertension, 2015, 65, 507-509.	2.7	34
42	The SPARTACUS Trial: Controversies and Unresolved Issues. Hormone and Metabolic Research, 2017, 49, 936-942.	1.5	33
43	Renin-Angiotensin-Aldosterone System Triple-A Analysis for the Screening of Primary Aldosteronism. Hypertension, 2020, 75, 163-172.	2.7	33
44	Diagnostic approach to lowâ€renin hypertension. Clinical Endocrinology, 2018, 89, 385-396.	2.4	32
45	Pharmacological Treatment of Arterial Hypertension in Children and Adolescents. Hypertension, 2018, 72, 306-313.	2.7	32
46	Diagnosis and treatment of primary aldosteronism. Reviews in Endocrine and Metabolic Disorders, 2011, 12, 3-9.	5.7	30
47	Histological Characterization of Aldosterone-producing Adrenocortical Adenomas with Different Somatic Mutations. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e282-e289.	3.6	29
48	Antecedent Administration of Angiotensinâ€Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVIDâ€19 Syndrome. Journal of the American Heart Association, 2020, 9, e017364.	3.7	29
49	Association Between Lifestyle and Systemic Arterial Hypertension in Young Adults: A National, Survey-Based, Cross-Sectional Study. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 31-40.	2.2	28
50	An extracellular vesicle epitope profile is associated with acute myocardial infarction. Journal of Cellular and Molecular Medicine, 2020, 24, 9945-9957.	3.6	27
51	Role of Extracellular Vesicles in the Pathogenesis of Vascular Damage. Hypertension, 2022, 79, 863-873.	2.7	27
52	Adrenal Venous Sampling–Guided Adrenalectomy Rates in Primary Aldosteronism: Results of an International Cohort (AVSTAT). Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1400-e1407.	3.6	25
53	Polyuric-polydipsic syndrome in a pediatric case of non-glucocorticoid remediable familial hyperaldosteronism. Endocrine Journal, 2012, 59, 497-502.	1.6	24
54	Characterization and Gene Expression Analysis of Serum-Derived Extracellular Vesicles in Primary Aldosteronism. Hypertension, 2019, 74, 359-367.	2.7	23

#	Article	IF	CITATIONS
55	Evaluation of primary aldosteronism. Current Opinion in Endocrinology, Diabetes and Obesity, 2010, 17, 188-193.	2.3	21
56	Effectiveness of Renal Denervation in Resistant Hypertension: A Meta-Analysis of 11 Controlled Studies. High Blood Pressure and Cardiovascular Prevention, 2018, 25, 167-176.	2.2	20
57	Genes implicated in insulin resistance are down-regulated in primary aldosteronism patients. Molecular and Cellular Endocrinology, 2012, 355, 162-168.	3.2	18
58	The spectrum of low-renin hypertension. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101399.	4.7	17
59	Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3655-e3664.	3.6	16
60	Development of a Prediction Score to Avoid Confirmatory Testing in Patients With Suspected Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1708-1716.	3.6	16
61	Genomic and Non-genomic Effects of Aldosterone. Current Signal Transduction Therapy, 2012, 7, 132-141.	0.5	16
62	Is Familial Hyperaldosteronism Underdiagnosed in Hypertensive Children?. Hypertension, 2011, 57, 1053-1055.	2.7	15
63	Primary Aldosteronism and Obstructive Sleep Apnea: Casual Association or Pathophysiological Link?. Hormone and Metabolic Research, 2020, 52, 366-372.	1.5	14
64	Characterization of Circulating Extracellular Vesicle Surface Antigens in Patients With Primary Aldosteronism. Hypertension, 2021, 78, 726-737.	2.7	14
65	Primary aldosteronism in the primary care setting. Current Opinion in Endocrinology, Diabetes and Obesity, 2018, 25, 155-159.	2.3	12
66	Primary Aldosteronism in the Elderly. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2320-e2326.	3.6	12
67	Profiling Inflammatory Extracellular Vesicles in Plasma and Cerebrospinal Fluid: An Optimized Diagnostic Model for Parkinson's Disease. Biomedicines, 2021, 9, 230.	3.2	12
68	Risk stratification of patients with SARS-CoV-2 by tissue factor expression in circulating extracellular vesicles. Vascular Pharmacology, 2022, 145, 106999.	2.1	11
69	Clinical Score and Machine Learning-Based Model to Predict Diagnosis of Primary Aldosteronism in Arterial Hypertension. Hypertension, 2021, 78, 1595-1604.	2.7	10
70	Diagnosis and Treatment of Unilateral Forms of Primary Aldosteronism. Current Hypertension Reviews, 2013, 9, 156-165.	0.9	9
71	Primary aldosteronism in pregnancy. Reviews in Endocrine and Metabolic Disorders, 2023, 24, 39-48.	5.7	9
72	Molecular and Electrophysiological Analyses of ATP2B4 Gene Variants in Bilateral Adrenal Hyperaldosteronism. Hormones and Cancer, 2020, 11, 52-62.	4.9	8

#	Article	IF	Citations
73	Prediction of hyperaldosteronism subtypes when adrenal vein sampling is unilaterally successful. European Journal of Endocrinology, 2020, 183, 657-667.	3.7	8
74	Supervised and unsupervised learning to define the cardiovascular risk of patients according to an extracellular vesicle molecular signature. Translational Research, 2022, , .	5.0	8
75	Diagnosis of primary aldosteronism in the hypertension specialist centers in Italy: a national survey. Journal of Human Hypertension, 2018, 32, 745-751.	2.2	7
76	Quality of life in primary aldosteronism: A prospective observational study. European Journal of Clinical Investigation, 2021, 51, e13419.	3.4	7
77	Rapid Cortisol Assay Increases the Success of Adrenal Vein Sampling. American Journal of Hypertension, 2011, 24, 1265-1265.	2.0	5
78	Role of Cryptochrome-1 and Cryptochrome-2 in Aldosterone-Producing Adenomas and Adrenocortical Cells. International Journal of Molecular Sciences, 2018, 19, 1675.	4.1	5
79	Atypical secondary hypertension due to mid-aortic syndrome. European Heart Journal, 2012, 33, 2248-2248.	2.2	3
80	Hyperaldosteronism: How to Discriminate Among Different Disease Forms?. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 203-208.	2.2	3
81	A Case of Adrenal Vein Sampling in Primary Aldosteronism With Homolateral Suppression. Journal of the Endocrine Society, 2017, 1, 401-406.	0.2	3
82	Usefulness of Combined Renin-Angiotensin System Inhibitors and Diuretic Treatment In Patients Hospitalized with COVID-19. American Journal of Cardiology, 2022, , .	1.6	3
83	Inpatient Mortality According to Level of Respiratory Support Received for Severe Acute Respiratory Syndrome Coronavirus 2 (Coronavirus Disease 2019) Infection: A Prospective Multicenter Study., 2020, 2, e0220.		2
84	Prediction of All-Cause Mortality Following Percutaneous Coronary Intervention in Bifurcation Lesions Using Machine Learning Algorithms. Journal of Personalized Medicine, 2022, 12, 990.	2.5	2
85	Primary Aldosteronism: Progress in Diagnosis, Therapy, and Genetics. , 2013, , 3-32.		1
86	Regulation of Aldosterone Production. , 2018, , 429-449.		1
87	Evaluation of Unattended Automated Office, Conventional Office and Ambulatory Blood Pressure Measurements and Their Correlation with Target Organ Damage in an Outpatient Population of Hypertensives: Study Design and Methodological Aspects. High Blood Pressure and Cardiovascular Prevention, 2019, 26, 493-499.	2.2	1
88	Familial Hyperaldosteronism. Updates in Hypertension and Cardiovascular Protection, 2020, , 79-93.	0.1	1
89	Genetics of Familial Hyperaldosteronism. , 2019, , 623-630.		1
90	Gender differences in acute coronary syndromes patterns during the COVID-19 outbreak. American Journal of Cardiovascular Disease, 2020, 10, 506-513.	0.5	1

#	Article	IF	CITATIONS
91	Controversies on the Diagnosis of Primary Aldosteronism. High Blood Pressure and Cardiovascular Prevention, 2006, 13, 173-178.	2.2	O
92	Diabetes in Hyperaldosteronism. Frontiers in Diabetes, 2014, , 34-43.	0.4	O
93	Issues in the Diagnosis and Treatment of Primary Aldosteronism. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 73-82.	2.2	O
94	Procedural Reassessment of Radiofrequency Renal Denervation in Resistant Hypertensive Patients. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 187-192.	2.2	0
95	Assessment of Anti-Hypertensive Drug Adherence by Serial Aldosterone-To-Renin Ratio Measurement. Frontiers in Pharmacology, 2021, 12, 668843.	3.5	O
96	Response to Letter to the Editor from Rossi and Rossitto: "Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism― Journal of Clinical Endocrinology and Metabolism, 2022, 107, e896-e897.	3.6	0
97	Familial Hyperaldosteronism Type I. , 2014, , 75-86.		O
98	Familial Hyperaldosteronism Type III. , 2014, , 99-108.		0